GH7 (GH3 Improved)
Why did 35,000 GH3 users change to GH7?
Gerovital H3, known as GH3, was developed and first systematically investigated
by Dr. Ana Aslan the Director of the Parhon Institute of Gerontology in Bucharest, Romania.
Dr. Aslan was born January 1, 1897. She graduated in 1924 from the School of Medicine in Bucharest, Romania
with honors. She became interested in the effects of procaine hydrochloride (procaine HCl) on aging patients.
Her interest had been sparked by studies she encountered by Doctors Leriche and Ghali who had used procaine
HCl injections to relieve the pain of arthritis. Since she had been recently appointed as the director of the
Geriatrics Clinic, she wanted to find a way to help those older individuals that were suffering from arthritis.
She found that by injecting a 2% solution of procaine HCl into the patient the pain was relieved. This was no
surprise, since procaine HCl is known as Novocaine which is used as an anesthetic. The effects of novocaine as
an anesthetic wear off after 1 or 2 hours. Dr. Aslan was amazed that with continued use the pain would stay
away not for hours, but for days, then months. Not only did the injections relieve the pain but there was
evidence of repair in the arthritic joints. Dr. Aslans team of researchers also documented that there were
improvements of skin, their skin was more supple and skin lesions were healed. They also noticed that those
that had symtoms of depression improved. Some with parkinsons disease were improving..
For more details of this history refer to the book “GH3 Will it
Keep You Young Longer” by Herbert Bailey
The procaine solution used by Dr. Aslan had been modified in order to produce the results. Her original results
with a solution of procaine were poor because of the unstable nature of the solution. They stablized the
solution of procaine by adding benzoic acid and buffering agents to shift the pH of the procaine solution from
5.5 to 3.5. This stablized solution of Procaine HCl Dr. Aslan named Gerovital H3 or GH3.
Dr. Aslan dedicated her life to helping the problems of the aging. She never married, her family was her
patients. She died in 1988 at the age of 91. She received many scientific and humanitarian honors during
her life. She was a warm, kind, generous lady and a remarkable scientist who left a great legacy to the world.
GH3 has been the center of much scientific controversy through the years, but the 54 years that it has been
in use by tens of thousands of people throughout the world has proven it to be a very powerful, safe, weapon
against aging and various degenerative diseases.
DEVELOPMENT OF GH7
Robert Koch, DSc. biochemist and inventor of many chemical processes became interested in GH3 in 1981.
Dr. Koch’s sister, who suffered from asthma found out about GH3 and obtained some through a friend. The
GH3 was very effective in controlling her asthma, to such a degree that Dr. Koch became interested in why
this anesthetic procaine HCl could be effective against asthma. He did a literature search in the Medical
Library and to his amazement there were over 600 articles about the benefits of GH3 and of various other
cellular benefits of procaine HCl. Since that time Dr. Koch has spent his time researching the effects of
procaine HCl on degenerative diseases. A company that was making GH3 here in the U.S. had Dr. Koch test
their GH3 tablets and he found that the tablets were nothing more than a mixture of the powders that make
up GH3, they didn’t contain the GH3 factor that was the effective agent in the Aslan injectables. He tested
some of the Romanian tablets and found that they didn’t contain the GH3 factor that was contained in the
injectable. They to were no more than a mixture of the powders, tableted.
When Dr. Aslan stabilized the procaine HCl solution with benzoic acid she didn’t realize that the benzoic
acid did more than acidify and stabilize the procaine HCL solution. The Benzoic acid reacted chemically with
the procaine HCL forming a double salt.
The chemical structure of the double salt protected the procaine from being destroyed in the blood stream
by the cholinesterase enzyme thus increasing the half life of the procaine from 0.6 minutes (36 seconds) to
over 6 hours.
This increased life of the procaine gave it time to transport into the cells where it is able to cause the cell
to rebuild membranes, thus revitalizing the cell function. This rejuvenation improves the ability of the cell
to feed itself and to get rid of harmful by products. The cell function improves. These healthier cells are
able to make repairs and get rid of abnormal problems that the cells have, mainly degenerative diseases.
Dr. Koch developed a process for producing the GH3 factor and then incorporating it into tablets that he
named GH3. This GH3 factor or benzoate double salt of procaine contains benzoic acid which has no
beneficial effect except to stabilize the procaine and since benzoic acid can be an allergen federal law limits
the amount of benzoates that can be added to foods etc..
The amount of benzoic acid in GH3 only protects 15% of the procaine. Dr. Koch surmised, “why not complex the
procaine with materials that are beneficial and protect 100% of the procaine?” This he did forming a whole new
series of compounds which he was able to patent.** He developed processes complexing the procaine with B
vitamins, vitamin C, with amino acids and with many other bio-active compounds. The combination of these
procaine double salts he named GH7. This combination of complexes provides protection for 100%
of the procaine as well as improving the revitalizing benefits of the procaine. The GH7 is about 6 times more
potent than GH3 because of the total complexing of the procaine.
THIS IS WHY THE 35,000 GH3 USERS SWITCHED TO GH7
The only reason that the other users of GH3 haven’t switched is
because they don’t know about it. It isone of the worlds best kept
secrets. If a company advertises GH-7 or a product under a different
name but was manufactured under the Koch patents then it will be
a genuine product.